Uplizna

(Inebilizumab-cdon)

Uplizna

Drug updated on 11/15/2023

Dosage FormInjection (intravenous:100 mg/10 mL (10 mg/mL) solution in a single-dose vial)
Drug ClassCD19-directed cytolytic antibodies
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • For the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.

Product Monograph / Prescribing Information

Document TitleYearSource
Uplizna (inebilizumab-cdon) Prescribing Information.2021Horizon Therapeutics USA, Inc., Deerfield, IL

Systematic Reviews / Meta-Analyses